Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Telix Pharmaceuticals Ltd
TLXCurrent price
22.9 AUD
0 AUD (0.00%)
Last closed
22.91 AUD
Company
telixpharma.com
ISIN
AU000000TLX2
Sector
Healthcare
Industry
Biotechnology
Exchange
Australian Securities Exchange
Capitalization
7 985 096 874 AUD
Yield for 12 month
+143.88 %
1Y
3Y
5Y
10Y
15Y
TLX
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. Its products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for brain (glioma) cancer; TLX66-CDx to treat bone marrow conditioning; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; and TLX250 for the treatment of clear cell renal cell carcinoma. The company also develops TLX101 for the treatment of glioblastoma (brain cancer); TLX66 for the treatment of bone marrow conditioning; TLX300 for the treatment of soft tissue sarcoma; and TLX592, a prostate cancer therapy candidate for targeted alpha therapy. Telix Pharmaceuticals Limited was founded in 2015 and is headquartered in North Melbourne, Australia. Address: 55 Flemington Road, North Melbourne, VIC, Australia, 3051
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
40.15 AUDP/E ratio
156.3333Dividend Yield
–Current Year
+505 314 740 AUD
Last Year
+162 886 142 AUD
Current Quarter
+192 256 234 AUD
Last Quarter
+286 622 676 AUD
Current Year
+313 878 552 AUD
Last Year
+29 848 285 AUD
Current Quarter
+126 039 990 AUD
Last Quarter
+227 878 422 AUD
Key Figures TLX
1 year
3 years
5 years
10 years
EBITDA
74 416 714 AUD
Operating Margin TTM
PE Ratio
156.3333
Return On Assets TTM
7.97 %
PEG Ratio
–
Return On Equity TTM
20.49 %
Wall Street Target Price
40.15 AUD
Revenue TTM
656 929 808 AUD
Book Value
1.23 AUD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
58.1 %
Dividend Yield
–
Gross Profit TTM
100 257 349 AUD
Earnings per share
0.15 AUD
Diluted Eps TTM
0.15 AUD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
7.62 %
Dividend Analytics TLX
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History TLX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation TLX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
156.3333
Forward PE
67.5676
Enterprise Value Revenue
12.1097
Price Sales TTM
12.1552
Enterprise Value EBITDA
105.7317
Price Book MRQ
19.3367
Financials TLX
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators TLX
For 52 weeks
9.1 AUD
24.01 AUD
50 Day MA
20.79 AUD
Shares Short Prior Month
–
200 Day MA
17.07 AUD
Short Ratio
–
Shares Short
–
Short Percent
–
BeatStart